Hikal Ltd
Hikal Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact. Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with plans intact despite a 2-3 year delay.
From Hikal Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact.
- Animal Health business is projected to scale meaningfully over several years, supported by commercialization of existing programs and new CDMO opportunities.
- Pharma business volume growth is anticipated in FY '27, with quarter-on-quarter improvement expected, although no specific guidance will be given until Q1 FY '27 results.
- Crop business volume growth is positive but expected to be modest; growth will mainly come from Pharma, Animal Health, and Specialty Chemicals divisions.
- The company aims for a top-line business of INR 500 crores plus in Animal Health within 4-5 years.
- Long-term growth target remains INR 3,500 to 4,000 crores by FY '30, though delayed by 2-3 years.
- Capital investments and strategic initiatives are expected to drive growth and improve margins going forward.
Profitability & Margins
See what Hikal Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Significant investment of about INR900 crores over the last 4 years, with INR600 crores in growth capex and INR300 crores in infrastructure and regulatory/maintenance capex.
- INR300 crores growth capex invested in multipurpose assets being retooled for Pharma and Animal Health business.
- New high-potency laboratory and expanded R&D center in Pune operational to enhance complex chemistry capabilities.
- New pilot plant at U.S. FDA-approved Panoli facility to support growth.
- Planned HPAPI manufacturing facility in Pune targeted for FY '28.
- FY '26 capital expenditure of INR149 crores for debottlenecking, regulatory upgrades, and expanding CDMO capacities.
- Strategic investments made in the last 12-15 months becoming operational to support next phase of growth.
- Ongoing investments to upgrade quality systems and implement CAPA for regulatory compliance.
- Retooling of agrochemical multipurpose plant at Panoli into a pharmaceutical facility underway, with expected revenue generation starting next financial year.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The order book for Hikal Limited remains intact despite recent challenges.
- There was a loss of business in Q4 due to FDA-related slowdowns, but recovery is expected in the next few quarters.
- CDMO segment continues to have long-term orders and engagements.
- Animal Health business is progressing well with validated products moving into the commercial phase.
- Encouraging inquiries and RFPs received from global customers, indicating a strong commercial pipeline.
- Customers have approved and reapproved facilities post-FDA issues, showing confidence and ongoing partnerships.
- Order book visibility is positive with gradual improvement in volumes and commercial traction across divisions.
Hikal Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hikal Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Hikal Ltd Q4 FY26 results?
Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact. Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with plans intact despite a 2-3 year delay.
What is Hikal Ltd share price analysis?
Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hikal Ltd planning capital expenditure?
Significant investment of about INR900 crores over the last 4 years, with INR600 crores in growth capex and INR300 crores in infrastructure and regulatory/maintenance capex. - INR300 crores growth capex invested in multipurpose assets being retooled for Pharma and Animal Health business. - New high-potency laboratory and expanded R&D center in Pune operational to enhance complex chemistry capabilities. - New pilot plant at U.S.
Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.